@Tooheys8
Happy to be corrected, I suspect it is basically because it provides 'immediate access' to a much larger patient 'data-set' to move the 'breadth' of the testing/assessments forward far more quickly than waiting (and paying) for access to 'fresh' new-samples as they become available...
Reading between the lines, it seems exosomes have a 'shelf-life' as such, so will basically required UQ & IIQ to 'revert' to basically acquiring access to 'fresh samples' on an ongoing basis to move the test forward (get 'statistical runs' on the board with a significant sample size), collate and then, present to industry, hence the H2FY24 delay-statement...
ML
Ann: EXO-OC PROGRAM COMPLETES SERUM EQUIVALENCE STUDY, page-13
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
-0.015(3.13%) |
Mkt cap ! $42.78M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.0¢ | 46.5¢ | $115.2K | 246.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 38383 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.0¢ | 4404 | 2 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
48.0¢ |
Change
-0.015 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 47.5¢ | 48.0¢ | 47.5¢ | 6707 | ||
| Last updated 15.07pm 30/05/2024 ? | |||||
| IIQ (ASX) Chart |